Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

Novavax, Inc.

2022/4/19 16:37

PR95515

GAITHERSBURG, Md., April 19, 2022 /PRNewswire=KYODO JBN/ --

- New data on COVID-19 Influenza combination vaccine and seasonal influenza

vaccine to be presented at World Vaccine Congress

- Several abstracts and presentations slated to highlight updates on

NVX-CoV2373, Novavax' COVID-19 vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing

and commercializing next-generation vaccines for serious infectious diseases,

will provide a first look at data from its COVID-19 influenza combination

vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress [

https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1840594479&u=https%3A%2F%2Fwww.terrapinn.com%2Fconference%2Fworld-vaccine-congress-washington%2Findex.stm&a=World+Vaccine+Congress

] (WVC) in Washington, DC, April 18 - 21, 2022. In addition, the latest data on

its protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be presented at

both WVC and the 32nd European Congress of Clinical Microbiology & Infectious

Diseases [

https://c212.net/c/link/?t=0&l=en&o=3507542-1&h=1505958255&u=https%3A%2F%2Fwww.eccmid.org%2F&a=32nd+European+Congress+of+Clinical+Microbiology+%26+Infectious+Diseases

] (ECCMID) in in Lisbon, Portugal, April 23 - 26, 2022. Data from eight

abstracts and presentations, including four oral presentations, will be

presented across the two congresses.

Gregory M. Glenn, M.D., President, Research and Development, Novavax, said:

"Our presence at these two leading industry conferences shows our ongoing

commitment to addressing COVID-19, and the advances we have made towards a

next-generation influenza vaccine. We look forward to sharing these updates

that further demonstrate the potential for our platform."

Key Novavax presentations during WVC:

Glenn, G	How long will our immunity against COVID-19 last for and will our vaccines continue to work against VoCs?	Panel April 19, 2022 8:45 – 9:45 ET
Kim, D	Monitoring COVID-19 Vaccine Safety under Emergency Use Authorization: Challenges and Lessons?	Panel April 20, 2022 12:10 – 1:10 ET
Glenn, G	Clinical Update on Novavax's Recombinant Nanoparticle Protein Subunit COVID-19 Vaccine as a Booster	Oral Session COVID & Beyond – M4 April 20, 2022 12:40 – 1:00 ET
Shinde, V	Update on Novavax' NanoFlu* vaccine and COVID-19-Influenza Combination Vaccine development	Oral Session Influenza and Respiratory – M4 April 20, 2022 12:40 – 1:10 ET

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle

influenza vaccine candidate produced by Novavax. This investigational candidate

was evaluated during a controlled phase 3 trial conducted during the 2019-2020

influenza season.

Key Novavax presentations during ECCMID:

Toback, S	Ongoing safety and efficacy of the NVX-CoV2373 COVID-19 vaccine in the United Kingdom	Abstract #04525 Oral Session Late breaking updates on COVID vaccination April 25, 2022 16:15 – 17:15 CET
Shinde, V	Long-term durability of antigen-specific polyfunctional CD4+ T cell responses against vaccine-homologous and antigenically drifted viruses: results of a phase III trial of a recombinant quadrivalent hemagglutinin saponin-adjuvanted nanoparticle influenza	Abstract #1197 Oral Session Viral respiratory infections: Influenza and RSV April 26, 2022 11:00 – 12:00 CET
Áñez, G	Safety, efficacy and effectiveness of a SARS-CoV-2 adjuvanted recombinant spike protein vaccine (NVX-CoV2373) in a phase III trial in adolescents (PREVENT-19)	Abstract #04455 Poster Session 12g. Vaccine development, trials, efficacy, policy April 25, 2022 12:00 – 13:00 CET
Áñez, G	Molecular epidemiology of SARS-CoV-2 strains identified during a phase III, efficacy and safety trial of NVX-CoV2373 vaccine (PREVENT-19) in the United States and Mexico	Abstract #00284 Poster Session 12l. Virus evolution, variants, and impact April 25, 2022 12:00 – 13:00 CET
Beyhaghi, H	Reported pregnancies and associated outcomes across the NVX-CoV2373 COVID-19 vaccine clinical development programme	Abstract #01705 Poster Session 12g. Vaccine development, trials, efficacy, policy April 25, 2022 12:00 – 13:00 CET
Marchese, A	COVID-19 vaccine receptivity and preferences among "vaccine hesitants"	Abstract #04362 Poster Session 12g. Vaccine development, trials, efficacy, policy April 25, 2022 12:00 – 13:00 CET